{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:47:00Z","timestamp":1789001220561,"version":"build-2803163510"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2495,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      <jats:bold>Primary biliary cirrhosis (PBC) is sometimes diagnosed based on a positive antimitochondrial antibody in the appropriate clinical setting without a liver biopsy. Although a liver biopsy can assess the extent of liver fibrosis and provide prognostic information, serum fibrosis markers avoid biopsy complications and sampling error and provide results as a continuous variable, which may be more precise than categorical histological stages. The current study was undertaken to evaluate serum fibrosis markers as predictors of clinical progression in a large cohort of PBC patients. Serial liver biopsy specimens and serum samples were collected every 2 years in 161 PBC subjects for a median of 7.3 years. Clinical progression was defined as development of one or more of the following events: varices, variceal bleed, ascites, encephalopathy, liver transplantation, or liver-related death. Serum hyaluronic acid, tissue inhibitor of metalloproteinase 1, and procollagen III aminopeptide were measured and entered into the previously validated enhanced liver fibrosis (ELF) algorithm. The ability of ELF, histological fibrosis, bilirubin, Model for End-Stage Liver Disease (MELD), and Mayo Risk Score to differentiate between individuals who would experience a clinical event from those who would not was evaluated at different time points. Event-free survival was significantly lower in those with high baseline ELF. Each 1-point increase in ELF was associated with a threefold increase in future complications. The prognostic performance of all tests was similar when performed close to the time of the first event. However, at earlier times in the disease process (4 and 6 years before the first event), the prognostic performance of ELF was significantly better than MELD or Mayo R score.<\/jats:bold>\n                      <jats:bold>Conclusion:<\/jats:bold>\n                      <jats:bold>The ELF algorithm is a highly accurate noninvasive measure of PBC disease severity that provides useful long-term prognostic information. (Hepatology 2008.)<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.22517","type":"journal-article","created":{"date-parts":[[2008,7,9]],"date-time":"2008-07-09T09:06:30Z","timestamp":1215594390000},"page":"1549-1557","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":172,"title":["Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay"],"prefix":"10.1097","volume":"48","author":[{"given":"Marlyn J.","family":"Mayo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Parkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Adams-Huet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burton","family":"Combes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney S.","family":"Markin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Contos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. B.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Saldana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonas","family":"Getachew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Butsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velimir","family":"Luketic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Di Bisceglie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Bass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"Garcia-Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-24-20241201","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis.","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"key":"R2-24-20241201","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.cgh.2006.07.006","article-title":"Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group.","volume":"4","author":"McHutchison","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R3-24-20241201","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2004.08.052","article-title":"Serum markers detect the presence of liver fibrosis: a cohort study.","volume":"127","author":"Rosenberg","year":"2004","journal-title":"Gastroenterology"},{"key":"R4-24-20241201","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-230X-6-6","article-title":"Diagnostic value of biochemical markers (FibroTestFibroSURE) for the prediction of liver fibrosis in patients with nonalcoholic fatty liver disease.","volume":"6","author":"Ratziu","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"R5-24-20241201","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1542-3565(04)00625-1","article-title":"Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.","volume":"3","author":"Naveau","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R6-24-20241201","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0168-8278(03)00184-3","article-title":"Serum levels of YKL40 and PIIINP as prognostic markers in patients with alcoholic liver disease.","volume":"39","author":"Nojgaard","year":"2003","journal-title":"J Hepatol"},{"key":"R7-24-20241201","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1373\/clinchem.2006.070961","article-title":"A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C.","volume":"52","author":"Ngo","year":"2006","journal-title":"Clin Chem"},{"key":"R8-24-20241201","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep.20897","article-title":"Methotrexate (MTZ) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.","volume":"42","author":"Combes","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R9-24-20241201","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis.","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"R10-24-20241201","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"R11-24-20241201","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","article-title":"Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis).","volume":"379","author":"Ludwig","year":"1978","journal-title":"Virchows Arch A Pathol Anat Histol"},{"key":"R13-24-20241201","first-page":"1257","article-title":"Primary biliary cirrhosis.","volume":"60","author":"Scheuer","year":"1967","journal-title":"Proc R Soc Med"},{"key":"R14-24-20241201","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/cgh.2003.50014","article-title":"When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?","volume":"1","author":"Zein","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R15-24-20241201","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0140-6736(00)04258-6","article-title":"Poynard T, for the MULTIVIRC group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.","volume":"357","author":"ImbertBismut","year":"2001","journal-title":"Lancet"},{"key":"R16-24-20241201","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1136\/gut.2006.091454","article-title":"Noninvasive markers associated with liver fibrosis in nonalcoholic fatty liver disease.","volume":"55","author":"Guha","year":"2006","journal-title":"Gut"},{"key":"R17-24-20241201","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.amjmed.2006.06.044","article-title":"Assessment of FIBROSpectII to detect hepatic fibrosis in chronic hepatitis C patients.","volume":"120","author":"Zaman","year":"2007","journal-title":"Am J Med"},{"key":"R18-24-20241201","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hep.21984","article-title":"Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers.","volume":"47","author":"Guha","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R19-24-20241201","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.","volume":"45","author":"Angulo","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R20-24-20241201","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1046\/j.1365-2893.2002.00341.x","article-title":"Biochemical markers of liver fibrosis inpatients infected by hepatitis C virius: longitudinal validation in a randomized trial.","volume":"9","author":"Poynard","year":"2002","journal-title":"J Virol Hepatitis"},{"key":"R21-24-20241201","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/jhep.2003.50319","article-title":"Biochemcial surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa2b and ribavirin.","volume":"38","author":"Poynard","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R22-24-20241201","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1111\/j.1572-0241.2002.05997.x","article-title":"Poynard T, for the MULTIVIRC group. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis c.","volume":"97","author":"Myers","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R23-24-20241201","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1023\/A:1021702902681","article-title":"Biochemical markers of fibrosis in patient with chronic hepatitis C: a comparison with prothrombin time, platelet count, and ageplatelet index.","volume":"48","author":"Myers","year":"2003","journal-title":"Dig Dis Sci"},{"key":"R24-24-20241201","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.hep.2003.10.010","article-title":"Liver biopsy size matters in chronic hepatitis: bigger is better.","volume":"38","author":"Scheuer","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R25-24-20241201","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(86)90883-4","article-title":"Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver.","volume":"8480","author":"Maharaj","year":"1986","journal-title":"Lancet"},{"key":"R26-24-20241201","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C.","volume":"38","author":"Bedossa","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R27-24-20241201","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/jcp.49.7.556","article-title":"Accuracy of staging in primary biliary cirrhosis.","volume":"49","author":"Garrido","year":"1996","journal-title":"J Clin Pathol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22517","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200811000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T08:35:49Z","timestamp":1733042149000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200811000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22517","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}